10 years since RE-LY: Comprehensive Experience for atrial Fibrillation Patients – ESC 2019

Chairpersons: John William Eikelboom (Hamilton, Canada), Gregory Yh Lip Liverpool, United Kingdom)

Subtitle: Sponsored by Boehringer Ingelheim

Learning Objectives: To evaluate the key milestones and innovations for non-Vitamin K antagonist oral anticoagulants (NOACs) in the past 10 year, and outline how these advances can inform treatment choices in patients with atrial fibrillation (AF) – To assess the evidence for the safety and efficacy of NOACs from clinical trials and real-world data – To provide practical guidance on anticoagulation decision making to optimize outcomes for a range of patients with AF, including those with challenging comorbidities and additional cardiovascular (CV) risk factors.

 

Introduction: celebrating a decade of innovation in atrial fibrillation
John William Eikelboom

 

NOAC safety profiles: assessing patient outcomes in the real world

Gregory Yh Lip

 

Quickfire questions and answers: NOAC safety profiles

 

Understanding atrial fibrillation patients with comorbidities

Associate Professor Anna Tomaszuk-Kazberuk

Quickfire questions and answers: anticoagulation in atrial fibrillation patients with cardiac comorbidities

 

Treating atrial fibrillation patients with cardiac comorbidities

Stefan H Hohnloser

 

Quickfire questions and answers: anticoagulation in atrial fibrillation patients with cardiac comorbidities

LEAVE YOUR COMMENT

Your email address will not be published.